Literature DB >> 26253731

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.

Daniela S Thommen1, Jens Schreiner2, Philipp Müller2, Petra Herzig2, Andreas Roller3, Anton Belousov3, Pablo Umana4, Pavel Pisa4, Christian Klein4, Marina Bacac4, Ozana S Fischer5, Wolfgang Moersig5, Spasenija Savic Prince6, Victor Levitsky4, Vaios Karanikas4, Didier Lardinois5, Alfred Zippelius1.   

Abstract

Dysfunctional T cells present in malignant lesions are characterized by a sustained and highly diverse expression of inhibitory receptors, also referred to as immune checkpoints. Yet, their relative functional significance in different cancer types remains incompletely understood. In this study, we provide a comprehensive characterization of the diversity and expression patterns of inhibitory receptors on tumor-infiltrating T cells from patients with non-small cell lung cancer. In spite of the large heterogeneity observed in the amount of PD-1, Tim-3, CTLA-4, LAG-3, and BTLA expressed on intratumoral CD8(+) T cells from 32 patients, a clear correlation was established between increased expression of these inhibitory coreceptors and progression of the disease. Notably, the latter was accompanied by a progressively impaired capacity of T cells to respond to polyclonal activation. Coexpression of several inhibitory receptors was gradually acquired, with early PD-1 and late LAG-3/BTLA expression. PD-1 blockade was able to restore T-cell function only in a subset of patients. A high percentage of PD-1(hi) T cells was correlated with poor restoration of T-cell function upon PD-1 blockade. Of note, PD-1(hi) expression marked a particularly dysfunctional T-cell subset characterized by coexpression of multiple inhibitory receptors and thus may assist in identifying patients likely to respond to inhibitory receptor-specific antibodies. Overall, these data may provide a framework for future personalized T-cell-based therapies aiming at restoration of tumor-infiltrating lymphocyte effector functions. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26253731     DOI: 10.1158/2326-6066.CIR-15-0097

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  110 in total

1.  Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Authors:  Jens Schreiner; Daniela S Thommen; Petra Herzig; Marina Bacac; Christian Klein; Andreas Roller; Anton Belousov; Victor Levitsky; Spasenija Savic; Wolfgang Moersig; Franziska Uhlenbrock; Viola A Heinzelmann-Schwarz; Pablo Umana; Pavel Pisa; M von Bergwelt-Baildon; Didier Lardinois; Philipp Müller; Vaios Karanikas; Alfred Zippelius
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

2.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Authors:  Michal A Stanczak; Shoib S Siddiqui; Marcel P Trefny; Daniela S Thommen; Kayluz Frias Boligan; Stephan von Gunten; Alexandar Tzankov; Lothar Tietze; Didier Lardinois; Viola Heinzelmann-Schwarz; Michael von Bergwelt-Baildon; Wu Zhang; Heinz-Josef Lenz; Younghun Han; Christopher I Amos; Mohammedyaseen Syedbasha; Adrian Egli; Frank Stenner; Daniel E Speiser; Ajit Varki; Alfred Zippelius; Heinz Läubli
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

Review 3.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

Review 4.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

5.  The characterization of lung microbiome in lung cancer patients with different clinicopathology.

Authors:  Danhui Huang; Xiaofang Su; Man Yuan; Shujia Zhang; Jing He; Qiuhua Deng; Wenjun Qiu; Hangming Dong; Shaoxi Cai
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 6.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

7.  Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

Authors:  Shaun M O'Brien; Astero Klampatsa; Jeffrey C Thompson; Marina C Martinez; Wei-Ting Hwang; Abishek S Rao; Jason E Standalick; Soyeon Kim; Edward Cantu; Leslie A Litzky; Sunil Singhal; Evgeniy B Eruslanov; Edmund K Moon; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2019-05-03       Impact factor: 11.151

8.  Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.

Authors:  C Y Hu; Y H Zhang; T Wang; L Chen; Z H Gong; Y S Wan; Q J Li; Y S Li; B Zhu
Journal:  Clin Exp Immunol       Date:  2016-08-23       Impact factor: 4.330

Review 9.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

Review 10.  Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.

Authors:  Diwakar Davar; Hassane M Zarour
Journal:  Methods Mol Biol       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.